CS MEDICA announces positive clinical trial results from the final report on NGA-01 gel & NSA-01 capsule (CANNASEN®CBD Arthritis Gel & CANNASEN®CBD ARTH Supplement) in combination against placebo
CS MEDICA (“CS MEDICA” or the “Company”) announces today that, after conducting the final efficacy analysis in their clinical trial, their CANNASEN®CBD Arthritis Gel & CANNASEN®CBD ARTH Supplement (NGA-01 gel and NSA-01 capsule), met all the trial’s primary and secondary efficacy, tolerability & safety endpoints. The final analysis was based on 60 cases of osteoarthritis. The trial data showed that both NGA-01 and NSA-01 were well tolerated, no adverse event was reported, and no significant changes were observed in the urinalysis. The results strengthen our product offering and improve our